RVMD – Revolution Medicines, Inc.
Float Short %
9.26
Margin Of Safety %
Put/Call OI Ratio
0.48
EPS Next Q Diff
-0.04
EPS Last/This Y
-1.96
EPS This/Next Y
-0.94
Price
118.79
Target Price
106.47
Analyst Recom
1
Performance Q
122.12
Relative Volume
0.98
Beta
0.97
Ticker: RVMD
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | RVMD | 80.72 | 0.16 | 2.49 | 39803 |
| 2025-12-29 | RVMD | 80.55 | 0.16 | 1.59 | 40011 |
| 2025-12-30 | RVMD | 79.67 | 0.16 | 0.57 | 40162 |
| 2025-12-31 | RVMD | 79.67 | 0.17 | 0.32 | 40451 |
| 2026-01-02 | RVMD | 79.02 | 0.17 | 2.54 | 40436 |
| 2026-01-05 | RVMD | 78.34 | 0.17 | 0.64 | 40789 |
| 2026-01-06 | RVMD | 79.8 | 0.17 | 0.30 | 40829 |
| 2026-01-07 | RVMD | 86.35 | 0.17 | 0.49 | 40800 |
| 2026-01-08 | RVMD | 107.42 | 0.24 | 0.39 | 50317 |
| 2026-01-09 | RVMD | 118.4 | 0.23 | 0.43 | 62979 |
| 2026-01-12 | RVMD | 117.06 | 0.32 | 0.72 | 98673 |
| 2026-01-13 | RVMD | 119.82 | 0.40 | 0.94 | 114458 |
| 2026-01-14 | RVMD | 121.2 | 0.42 | 0.78 | 119259 |
| 2026-01-15 | RVMD | 123.31 | 0.46 | 0.43 | 124636 |
| 2026-01-16 | RVMD | 120.52 | 0.47 | 2.38 | 125439 |
| 2026-01-20 | RVMD | 116.16 | 0.54 | 0.29 | 89535 |
| 2026-01-21 | RVMD | 117.52 | 0.52 | 0.07 | 102481 |
| 2026-01-22 | RVMD | 118.81 | 0.48 | 0.20 | 109284 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | RVMD | 80.74 | -42.4 | -256.5 | -5.54 |
| 2025-12-29 | RVMD | 80.53 | -42.4 | -260.5 | -5.54 |
| 2025-12-30 | RVMD | 79.68 | -42.4 | -249.2 | -5.54 |
| 2025-12-31 | RVMD | 79.67 | -42.4 | -264.1 | -5.54 |
| 2026-01-02 | RVMD | 79.01 | -42.4 | -252.8 | -5.54 |
| 2026-01-05 | RVMD | 78.32 | -42.4 | -251.7 | -5.54 |
| 2026-01-06 | RVMD | 79.81 | -42.4 | -294.4 | -5.54 |
| 2026-01-07 | RVMD | 88.00 | -42.4 | -414.8 | -5.54 |
| 2026-01-08 | RVMD | 107.36 | -39.8 | -329.4 | -5.54 |
| 2026-01-09 | RVMD | 118.79 | -39.8 | -415.9 | -5.54 |
| 2026-01-12 | RVMD | 117.14 | -39.8 | -246.8 | -5.54 |
| 2026-01-13 | RVMD | 119.91 | -39.8 | -297.7 | -5.54 |
| 2026-01-14 | RVMD | 121.09 | -39.8 | -278.0 | -5.54 |
| 2026-01-15 | RVMD | 123.26 | -39.8 | -288.3 | -5.54 |
| 2026-01-16 | RVMD | 120.28 | -39.8 | -230.5 | -5.54 |
| 2026-01-20 | RVMD | 116.18 | -39.8 | -216.6 | -5.54 |
| 2026-01-21 | RVMD | 117.52 | -39.8 | -280.8 | -5.54 |
| 2026-01-22 | RVMD | 118.79 | -39.8 | -280.5 | -5.54 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | RVMD | -1.37 | 1.24 | 9.12 |
| 2025-12-29 | RVMD | -1.37 | 1.24 | 9.12 |
| 2025-12-30 | RVMD | -1.37 | 1.24 | 9.12 |
| 2025-12-31 | RVMD | -1.37 | 1.24 | 9.12 |
| 2026-01-02 | RVMD | -1.37 | 1.24 | 9.12 |
| 2026-01-05 | RVMD | -1.37 | 1.24 | 9.12 |
| 2026-01-06 | RVMD | -1.37 | 1.24 | 9.12 |
| 2026-01-07 | RVMD | -1.37 | 1.24 | 9.12 |
| 2026-01-08 | RVMD | -1.37 | 1.24 | 9.12 |
| 2026-01-09 | RVMD | -1.66 | 1.24 | 9.12 |
| 2026-01-12 | RVMD | -1.83 | 1.23 | 9.12 |
| 2026-01-13 | RVMD | -1.66 | 1.23 | 9.26 |
| 2026-01-14 | RVMD | -1.66 | 1.23 | 9.26 |
| 2026-01-15 | RVMD | -1.66 | 1.23 | 9.26 |
| 2026-01-16 | RVMD | -1.66 | 1.23 | 9.26 |
| 2026-01-20 | RVMD | -1.66 | 2.01 | 9.26 |
| 2026-01-21 | RVMD | -1.66 | 2.01 | 9.26 |
| 2026-01-22 | RVMD | -1.66 | 2.01 | 9.26 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.61
Avg. EPS Est. Current Quarter
-1.6
Avg. EPS Est. Next Quarter
-1.65
Insider Transactions
-1.66
Institutional Transactions
2.01
Beta
0.97
Average Sales Estimate Current Quarter
2
Average Sales Estimate Next Quarter
Fair Value
Quality Score
6
Growth Score
22
Sentiment Score
79
Actual DrawDown %
4.6
Max Drawdown 5-Year %
-73.3
Target Price
106.47
P/E
Forward P/E
PEG
P/S
P/B
14.11
P/Free Cash Flow
EPS
-5.18
Average EPS Est. Cur. Y
-5.54
EPS Next Y. (Est.)
-6.48
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.98
Return on Equity vs Sector %
-87.4
Return on Equity vs Industry %
-71.5
EPS 1 7Days Diff
EPS 1 30Days Diff
0.03
EBIT Estimation
-280.5
Revolution Medicines, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 809
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading